A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

Summary Background This trial evaluated the safety, tolerability and maximum tolerated dose (MTD) of afatinib, a novel ErbB Family Blocker. Methods In this open-label, dose-escalation Phase I study, afatinib was administered continuously, orally, once-daily for 28 days to patients with advanced or m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2013-04, Vol.31 (2), p.409-416
Hauptverfasser:	Gordon, Michael S., Mendelson, David S., Gross, Mitchell, Uttenreuther-Fischer, Martina, Ould-Kaci, Mahmoud, Zhao, Yihua, Stopfer, Peter, Agus, David B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Breast cancer Cancer therapies Clinical trials Cohort Studies Diarrhea Dose-Response Relationship, Drug Drug Administration Schedule Drug dosages Female Follow-Up Studies General aspects Growth factors Humans Inhibitor drugs Ligands Male Maximum Tolerated Dose Medical sciences Medicine Medicine & Public Health Metastasis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nausea Neoplasms - drug therapy Oncology Palliative care Pharmacokinetics Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Phase I Studies Prognosis Quinazolines - pharmacokinetics Quinazolines - therapeutic use Studies Tissue Distribution Tumors Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!